The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Jiangsu Hengrui Medicine
Stock and Other Ownership Interests - Jiangsu Hengrui Medicine

A phase II study of anti–PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer.
 
Shukui Qin
No Relationships to Disclose
 
Zhendong Chen
No Relationships to Disclose
 
Ying Liu
No Relationships to Disclose
 
Jianping Xiong
No Relationships to Disclose
 
Zhenggang Ren
No Relationships to Disclose
 
Zhiqiang Meng
No Relationships to Disclose
 
ShanZhi Gu
No Relationships to Disclose
 
Linna Wang
Employment - Jiangsu Hengrui Medicine
 
Jianjun Zou
No Relationships to Disclose